Epigenomics and VSA receive approval to market Epi proColon

11-Mar-2014 - Argentina

Epigenomics AG and VSA ALTA COMPLEJIDAD S.A. announced that VSA has received approval to market the Epigenomics Epi proColon® kit for the blood-based detection of colorectal cancer (CRC) in Argentina.

“The Epigenomics assay enables VSA to extend its market leading efforts to improve access to colorectal cancer screening and reduce the colorectal cancer burden in Argentina,” said Luis Israel, CEO of VSA, “Due to late detection, mortality rates from colorectal cancer are still among the highest for males and females in our country, so we have made the launch and roll-out of the blood based assay a priority.”

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances